To unlock this feature and to subscribe to our weekly evidence emails, please create a FREE orthoEvidence account.


Already Have an Account?

Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Vol:2 Issue:7 Number:613 ISSN#:2564-2537
Author Verified
ACE Report #5102
Ace Report Cover Tumour

Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival

How to Cite

OrthoEvidence. Muramyl tripeptide in chemotherapy improves overall osteosarcoma survival. ACE Report. 2013;2(7):613. Available from:

Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A

Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group

J Clin Oncol. 2008 Feb 1;26(4):633-8. doi: 10.1200/JCO.2008.14.0095

Contributing Authors:
PA Meyers CL Schwartz MD Krailo JH Healey ML Bernstein D Betcher WS Ferguson MC Gebhardt AM Goorin M Harris E Kleinerman MP Link H Nadel M Nieder GP Siegal MA Weiner RJ Wells RB Womer HE Grier Children's Oncology Group

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Dr. Paul A. Meyers discusses the addition of muramyl tripeptide to chemotherapy in the treatment of Osteosarcoma.


662 osteosarcoma patients without detectable metastatic disease were either randomized to three drug (cisplatin, doxorubicin, methotrexate) or four drug chemotherapy (cisplatin, doxorubicin, methotrexate, and ifosfamide). A further comparison was conducted on the effects of the addition muramyl tri-peptide (MTP) to both chemotherapy regimens. Four- and six-year evaluations of event free survival (...

Ace Report Preview Image
CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.

For Reprints and Permissions, click here

Please Login or Join to leave comments.